Marnetegragene Autotemcel (Kresladi)
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.599 alerts
Get alerted when Policy CP.PHAR.599 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Kresladi, an autologous gene therapy for pediatric patients with severe leukocyte adhesion deficiency type 1 (LAD-I). It applies to QualChoice commercial, HIM/ICHRA, and Medicaid members and requires PDAC utilization management review.
The policy was updated after marnetegragene autotemcel became FDA approved, with criteria revised to align with FDA labeling.
The policy clarified that the ITGB2 gene mutation must be biallelic and added an age requirement of less than 18 years based on prescribing information.
Additional severe-disease options were added, including genetic testing, delayed umbilical cord separation, omphalitis, and LAD-I-related clinical events.
The generic name was added and the former designation RP-L201 was updated to Kresladi.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.